IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby ...
Universal Surveillance Monitoring with Masimo SET ® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost ...
Philips and Masimo are renewing their yearslong collaboration in patient monitoring with what they describe as an expanded focus on developing next-generation vital sign readers, plus a plan to work ...
Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...
On the earnings call in August, new CEO Katie Szyman, who joined Masimo in February from BD, sought to reassure investors that the company’s decades-long relationship with Philips remained strong.
Multi-Year Partnership Renewal with Broadened Focus Will Include Expedited Technology Adoption and Market-Based Strategic Development of Next-Generation Monitoring Solutions Building on over two ...
Noting that while the trend toward performing TJA as outpatient surgery reduces hospital length of stay (LOS), the practice decreases “available time to monitor for postoperative complications,”1 the ...
Masimo’s Rainbow Acoustic Monitoring sensor, RAS-125 Acoustic Respiration Cloth Sensor, was granted FDA 510(k) clearance for monitoring pediatric patients. Previously, clinicians could only use the ...
Masimo tightened its full-year 2025 revenue guidance to $1.510 billion to $1.530 billion, citing a $5 million adjustment at both the top and bottom ends. The company raised its operating margin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results